Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NM-1001 in Fragile X Syndrome
NCT05832255Phase 2Suspended
- Sponsor
- Nova Mentis
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of psilocybin in Fragile X syndrome (FXS), sponsored by Nova Mentis. Started Mar 2023; status: suspended.
02
Drugs
psilocybin
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT05832255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05832255.